Skip to main content

 29XK | pdb_000029xk

Full-length MICAL1 in the oxidized and autoinhibited state


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.19 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 29XK

This is version 1.0 of the entry. See complete history. 

Literature

NADPH gating and F-actin engagement define the structural bases of MICAL1 autoinhibition and activation.

Ballabio, F., Minari, A., Bonnet, D.M.V., Graziadei, A., Di Ianni, A., Nobile, M., Tedeschi, G., Camilloni, C., Chaves-Sanjuan, A., Vanoni, M.A.

(2026) Arch Biochem Biophys : 111023-111023

  • DOI: https://doi.org/10.1016/j.abb.2026.111023
  • Primary Citation Related Structures: 
    29XK, 29XL

  • PubMed Abstract: 

    Human MICAL1 is a multidomain protein exhibiting both an oxidase activity, producing H 2 O 2 as a second messenger, and an actin depolymerizing activity through the NADPH-dependent reaction catalyzed by its N-terminal flavoprotein domain. In full-length MICAL1, this domain is inhibited by the following protein regions. Interaction with activating (macro)molecules controls the timing and location of the enzyme activity, explaining its participation in diverse cellular processes. To gain insight into the reaction mechanism and its control, we combined kinetic, cryo-EM, chemical cross-linking and modeling studies of MICAL1, and of complexes with NADPH and F-actin. Contrary to previous models proposing an equilibrium between fully inactive and active conformations, the latter with the properties of the isolated catalytic domain, our results show that MICAL1 exists in solution in a single compact "autoinhibited" conformation able to bind and oxidize NADPH, although at a rate lower than that of the isolated catalytic domain. The reorientation of the gating Trp400 residue is required for productive binding of the nicotinamide portion of NADPH for hydride transfer to the FAD coenzyme, and is specifically hampered in full-length MICAL1 by the Trp400-Phe399-Arg933 triad. In complex with F-actin, the isolated flavoprotein domain bridges two adjacent actin subunits along the filament's ridge with the active site in proximity to, but not in direct contact with, the intersubunit actin interface supporting a mechanism of actin residues oxidation through H 2 O 2 diffusion from the enzyme active site. Model inspection suggests the conformational changes of full-length MICAL1 required for concomitant F-actin binding and relief of "autoinhibition".


  • Organizational Affiliation: 
    • Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy.

Macromolecule Content 

  • Total Structure Weight: 118.93 kDa 
  • Atom Count: 6,515 
  • Modeled Residue Count: 817 
  • Deposited Residue Count: 1,067 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
[F-actin]-monooxygenase MICAL11,067Homo sapiensMutation(s): 0 
Gene Names: MICAL1, MICAL, NICAL
EC: 1.14.13.225 (PDB Primary Data), 1.6.3.1 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for Q8TDZ2 (Homo sapiens)
Explore Q8TDZ2 
Go to UniProtKB:  Q8TDZ2
PHAROS:  Q8TDZ2
GTEx:  ENSG00000135596 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ8TDZ2
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.19 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
RECONSTRUCTIONcryoSPARC4.2.1

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2026-10-21
    Type: Initial release